Combination treatment with encorafenib and cetuximab, with or without binimetinib, showed significantly longer overall survival (OS) with a higher response rate than standard therapy in BRAF-MT CRC recently [14,15,16]. The gene discussed is BRAF; the disease is colorectal carcinoma.